Zobrazeno 1 - 4
of 4
pro vyhledávání: '"M. A. Al Jumah"'
Autor:
M. H. Abumaree, N. A. Alshehri, A. Almotery, A. M. Al Subayyil, E. Bahattab, F. M. Abomaray, T. Khatlani, B. Kalionis, D. Jawdat, M. F. El-Muzaini, M. A. Al Jumah, A. S. AlAskar
Publikováno v:
Stem Cell Research & Therapy, Vol 10, Iss 1, Pp 1-15 (2019)
Abstract Background Mesenchymal stem cells derived from the chorionic villi of human placentae (pMSCs) produce a unique array of mediators that regulate the essential cellular functions of their target cells. These properties make pMSCs attractive ca
Externí odkaz:
https://doaj.org/article/57490628abdd47b48a4f64184d188f5f
Autor:
F. M. Abomaray, M. A. Al Jumah, K. O. Alsaad, D. Jawdat, A. Al Khaldi, A. S. AlAskar, S. Al Harthy, A. M. Al Subayyil, T. Khatlani, A. O. Alawad, A. Alkushi, B. Kalionis, M. H. Abumaree
Publikováno v:
Stem Cells International, Vol 2016 (2016)
Mesenchymal stem cell (MSC) therapies for the treatment of diseases associated with inflammation and oxidative stress employ primarily bone marrow MSCs (BMMSCs) and other MSC types such as MSC from the chorionic villi of human term placentae (pMSCs).
Externí odkaz:
https://doaj.org/article/c0369c86db5d412996c544363e2bee4b
Background: Vaginal discharge is one of the most common complaints and reasons of gynecological consolation among women especially during reproductive age. Also, it represents a major problem for many women that affect their quality of life and cause
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::967411f58fd208d50a5bad754515984c
Autor:
Diener, H, Agosti, R, Allais, G, Bergmans, P, Bussone, G, Davies, B, Ertas, M, Lanteri Minet, M, Reuter, U, Del Río, MS, Schoenen, J, Schwalen, S, van Oene, J, TOPMAT MIG 303 Investigators Group, C. Lampl, T. Berger, J. Jacquy, L. Herroelen, P. Louis, J. Schoenen, I. Milanov, Z. Zahariev, S. Bozhinov, P. Dočekal, M. Grünermelová, G. Waberžinek, P. Tfelt Hansen, M. Groenbech Jensen, I. Tsiropoulos, R. Kirkeby, M. J. Rasmussen, D. Valade, H. Massiou, C. Sereni, A. Donnet, M. Lanteri Minet, C. Lucas, G. Mick, A. Pradalier, E. Guegan Massardier, H. C. Diener, S. Evers, U. Reuter, A. Straube, D. Mitsikostas, K. Karageorgiou, I. Milonas, G. Georgiadis, G. Gyula, Á. Judit, H. Péter, V. László, O. Hardiman, B. Sweeny, L. Grazzi, B. Colombo, G. Bruzzone, A. Quattrone, C. Benedetto, G. D'Andrea, P. Barbanti, R. De Simone, F. Valguarnera, M. A. Al Jumah, A. Al Tahan, I. Monstad, R. sj, R. Salvesen, LJ Stovner, H. Kwiecinski, W. Fryze, D. Pruchnik Wolinska, R. Motyl, W. Kozubsk, K. Ulatowska Blaszyk, A. Prusinski, L. Cunha, J. Pereira Monteiro, P. Esperança, A. Boyko, A. Skoromets, T. Pogačnik, T. Hojs Fabjan, M. Sánchez Del Río, R. Agosti, F. Donati, B. Tettenborn, M. Siccoli, A. Siva, M. Ertaş, M. Zarifoğlu, B. Davies, P. Davies, D. Bates, M. Fontebasso, P. Cleland, S. Lipscombe, A. Dowson, M. Lawden, S. McPhee, B. Calder, FERRARESE, CARLO
Publikováno v:
The Lancet Neurology. 6:1054-1062
BACKGROUND: Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22841f260663d94791b83518d646dfe
https://doi.org/10.1016/s1474-4422(07)70272-7
https://doi.org/10.1016/s1474-4422(07)70272-7